KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Accured Expenses: 2016-2024

Historic Change in Accured Expenses for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$385.0 million.

  • Moderna's Change in Accured Expenses rose 306.12% to $199.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$166.0 million, marking a year-over-year increase of 79.71%. This contributed to the annual value of -$385.0 million for FY2024, which is 13.24% down from last year.
  • Per Moderna's latest filing, its Change in Accured Expenses stood at -$385.0 million for FY2024, which was down 13.24% from -$340.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Change in Accured Expenses peaked at $989.0 million during FY2021, and registered a low of -$740.0 million during FY2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$385.0 million (2024), whereas its average is -$488.3 million.
  • In the last 5 years, Moderna's Change in Accured Expenses surged by 6,566.67% in 2020 and then crashed by 174.82% in 2022.
  • Moderna's Change in Accured Expenses (Yearly) stood at $388.0 million in 2020, then spiked by 154.90% to $989.0 million in 2021, then slumped by 174.82% to -$740.0 million in 2022, then spiked by 54.05% to -$340.0 million in 2023, then fell by 13.24% to -$385.0 million in 2024.